Artivion (NYSE:AORT) Given New $30.00 Price Target at Stifel Nicolaus

Artivion (NYSE:AORT) had its price objective decreased by Stifel Nicolaus from $33.00 to $30.00 in a report released on Tuesday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

AORT has been the topic of several other reports. Oppenheimer lifted their price target on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a research note on Tuesday, December 10th. Finally, Needham & Company LLC lowered their price target on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Artivion presently has an average rating of “Buy” and an average price target of $31.40.

Artivion Trading Down 9.1 %

Shares of NYSE:AORT opened at $25.33 on Tuesday. Artivion has a 12 month low of $18.38 and a 12 month high of $32.33. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The company’s fifty day simple moving average is $29.75 and its 200 day simple moving average is $27.83. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -1,266.25 and a beta of 1.75.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The business had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. As a group, research analysts forecast that Artivion will post 0.37 EPS for the current fiscal year.

Insider Activity

In related news, SVP Jean F. Holloway sold 8,070 shares of Artivion stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $30.12, for a total transaction of $243,068.40. Following the completion of the sale, the senior vice president now owns 153,862 shares of the company’s stock, valued at approximately $4,634,323.44. The trade was a 4.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Amy Horton sold 4,329 shares of Artivion stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $29.66, for a total transaction of $128,398.14. Following the sale, the chief accounting officer now directly owns 135,660 shares of the company’s stock, valued at $4,023,675.60. The trade was a 3.09 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 20,017 shares of company stock valued at $600,007 in the last quarter. Company insiders own 8.10% of the company’s stock.

Institutional Trading of Artivion

Several hedge funds and other institutional investors have recently modified their holdings of AORT. Creative Planning boosted its holdings in shares of Artivion by 182.1% during the 3rd quarter. Creative Planning now owns 28,635 shares of the company’s stock worth $762,000 after buying an additional 18,486 shares during the period. RiverPark Advisors LLC raised its stake in Artivion by 151.6% in the 3rd quarter. RiverPark Advisors LLC now owns 5,387 shares of the company’s stock worth $143,000 after purchasing an additional 3,246 shares in the last quarter. Quest Partners LLC raised its stake in Artivion by 2,481,700.0% in the 3rd quarter. Quest Partners LLC now owns 24,818 shares of the company’s stock worth $661,000 after purchasing an additional 24,817 shares in the last quarter. Intech Investment Management LLC raised its stake in Artivion by 6.6% in the 3rd quarter. Intech Investment Management LLC now owns 10,530 shares of the company’s stock worth $280,000 after purchasing an additional 653 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Artivion by 28.1% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,596 shares of the company’s stock worth $522,000 after purchasing an additional 4,295 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.